Renshaw Capital Group, Inc. (NASDAQ: RODM), today announced it has hired Dr. Simos Simeonidis as a Director and Senior Biotechnology Analyst who will cover the small and midcap biotechnology and specialty pharmaceuticals sector.
“Simos brings added depth and reach to our leading life science research team,” said Michael Lacovara, Rodman’s CEO, “and we believe his breadth of experience in biomedical research, academia, the laboratory and big pharma, as well as Wall Street will provide an unrivaled value proposition to our investor and company clients.”
Dr. Simos Simeonidis joins Rodman’s New York office from First Albany Capital where he was a Vice President and Senior Biotechnology Analyst covering the small and mid-cap biotechnology and specialty pharmaceuticals sector. Prior to this, Dr. Simeonidis was a member of the biotechnology equity research group at Morgan Stanley. Before that, he was an Associate Director in the Business Development/Licensing and Strategic Planning groups at Novartis. Dr. Simeonidis also brings additional industry experience through his tenure at GlaxoSmithKline’s Global Commercial Strategy group and Johnson & Johnson’s Venture Capital group.
Prior to his role as a research analyst, Dr. Simeonidis was a faculty member at Harvard Medical School and the Beth Israel Deaconess Medical Center. He has authored numerous articles in leading peer-reviewed biomedical journals and has academic experience at Columbia University, Northeastern Illinois University and Boston College. Dr. Simeonidis received his B.S. in Biology from Loyola University in Chicago, and his M.A., M.Phil. and Ph.D. in Cellular, Molecular and Biophysical Studies from Columbia University’s College of Physicians and Surgeons. He completed his postdoctoral fellowship at Harvard Medical School and the Brigham and Women’s Hospital and also received his MBA in Healthcare Management at The Wharton School.
About Rodman & Renshaw Capital Group, Inc.
Rodman & Renshaw Capital Group, Inc. is a holding company with a number of direct and indirect subsidiaries, including Rodman & Renshaw, LLC, Rodman Principal Investments, LLC and Miller Mathis & Co., LLC.
Rodman & Renshaw, LLC is a full service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies, along with research and sales and trading services to investor clients that focus on such companies. Rodman is a leading investment banking firm with particular emphasis on “essential” industries with significant capital needs, including health care (especially life science), energy (especially upstream oil and gas), ferrous and non-ferrous metals, shipping, and natural resources, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.